ERAP1 and asthma: Among these protein-disease pairs, three of them were related to proteins of existing drug targets, which included interleukin-17 receptor antagonist (IL-17RA) level on asthma, endoplasmic reticulum aminopeptidase 1 (ERAP1) level (target of tosedostat) on IPF, and NQO1 level (target of vatiquinone) on HF (Figure 2).